Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Greenwich LifeSciences, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 14.68M shares outstanding
USGreenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Leadership
Snehal S. Patel
Chief Executive Officer, Chief Financial Officer & Director
Eric Rothe
Founder & Independent Director
Christine T. Fischette
Vice President of Business Development
Frank Joseph Daugherty
Chief Medical Officer & Director
Employees
4
Country
US
Sector
Healthcare
Website
greenwichlifesciences.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Patel Snehal | CEO and CFO | Purchase | 700 | $9.2K | Jul 29, 2026 |
| Patel Snehal | CEO and CFO | Purchase | 1.5K | $20.4K | Jul 28, 2026 |
| Patel Snehal | CEO and CFO | Purchase | 1.5K | $20.4K | Jul 27, 2026 |
| Patel Snehal | CEO and CFO | Purchase | 1.1K | $14.2K | Jul 24, 2026 |
| Patel Snehal | CEO and CFO | Purchase | 2.5K | $32.9K | Jul 23, 2026 |
| Patel Snehal | CEO and CFO | Purchase | 1.8K | $53.7K | Jan 13, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
 Patel Snehal CEO and CFO, Director, 10% Owner | 5.6M | 38.2% | FORM 4 |
BlackRock, Inc. | 485.9K | 3.3% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 278.2K | 1.9% | 13F |
 Thompson Jaye VP Clinical Reg Affairs | 264.1K | 1.8% | FORM 4 |
GEODE CAPITAL MANAGEMENT, LLC | 168.2K | 1.1% | 13F |
STATE STREET CORP | 143.1K | 1.0% | 13F |
VANGUARD PORTFOLIO MANAGEMENT LLC | 80.9K | 0.6% | 13F |
NORTHERN TRUST CORP | 80.2K | 0.5% | 13F |
Bank of New York Mellon Corp | 47.9K | 0.3% | 13F |
VANGUARD FIDUCIARY TRUST CO | 46.0K | 0.3% | 13F |
Insiders
- Patel SnehalCEO and CFO
- McWilliams DavidDirector
- Rothe EricDirector
- Thompson JayeVP Clinical Reg Affairs
- Hallock KennethDirector
- Daugherty Frank JosephChief Medical Officer
based on 14.68M shares outstanding
US30d Avg
125.97K
60d Avg
122.07K
90d Avg
125.02K